|
KMID : 1170320130190020097
|
|
Korean Journal of Health Economics and Policy
2013 Volume.19 No. 2 p.97 ~ p.112
|
|
|
Comparing Pharmaceutical Pricing and Listing Policies in China to Korea
|
|
Lee Bo-Ram
Yu Su-Yeon
Jang Sun-Mee
|
|
|
Abstract
|
|
|
|
Pharmaceutical market in China is rapidly increasing with economic growth and large population. The purpose of this study is informing the pharmaceutical policy within the Chinese health insurance system. Basic drug classification of China is similar to Korea, but separation between TCM(Traditional Chinese Medicine) and Western Medicine is distinct feature. Chinese government establishes and administers National Basic Pharmaceutical Lists and The National Basic Medical Insurance Pharmaceutical Lists. However, the process or principle of registration is not transparent yet and companies have no chance to apply for registration. In the step of price determination after registration, the authority declares certain price or determines the maximum price, either. Such uncertainty of registration and price determination policy is a kind of risk for the pharmaceutical companies which are planning to set up business in China. Therefore, Chinese government`s priorities are the development of objective standard and enhancement of transparency with information disclosure before opening pharmaceutical market. Nevertheless, China`s health insurance expanding policy and market opening are becoming great opportunities to Korean pharmaceutical companies, so continuous examination on Chinese policy changes and long-term prospects are needed.
|
|
|
KEYWORD
|
|
|
China, health insurance, drug listing, pharmaceutical pricing
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|